Table 2.
Pattern of platelet count derangement before and after rituximab administration
| Baseline | First admission (10 days after first cycle of rituximab) | Baseline | Second admission (4 days after second cycle of rituximab) | Baseline | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Before initiation of rituximab | Day 1 | Day 2 | Day 3 | Day 5 | Day 10 | After recovery and before second cycle of rituximab | Day 1 | Day 5 | After recovery from second cycle of rituximab and on clinic review | |
| Hb (g/dL) | 11.3 | 11.8 | 10.0 | 10.0 | 10.7 | 11.1 | 11.7 | 10.2 | 10.7 | 12.1 |
| WBC (× 109/L) | 6.9 | 8.3 | 8.6 | 9.1 | 8.6 | 8.7 | 6.6 | 6.8 | 9.2 | 7.2 |
| Platelet (× 109/L) | 222 | 5 | 7 | 21 | 72 | 100 | 283 | 10 | 110 | 261 |
Hb, hemoglobin; WBC, white blood cells